Trial Profile
A Multi-National, Open-Label, Dose Escalation Trial, Evaluating Safety and Pharmacokinetics of Intravenous Doses of NNC 0129-0000-1003 in Patients With Haemophilia A
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Feb 2017
Price :
$35
*
At a glance
- Drugs Turoctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Adverse reactions
- Acronyms pathfinder 1
- Sponsors Novo Nordisk
- 24 Apr 2014 New trial record